Physician profile
Angela Miller
NPI 1740725837
$1,798.35
in general payments reported to CMS, 2019-2025
27 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.94 · 2022: $118 · 2023: $373 · 2024: $713 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.25 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $179.94 | 2023-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $163.57 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.97 | 2022-2025 | |
| Abbott Laboratories | $133.24 | 2022-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.41 | 2024 | Caplyta |
| Ironshore Pharmaceuticals INC. | $68.47 | 2023-2024 | Jornay Pm |
| Organon LLC | $62.39 | 2023-2024 | Nexplanon |
| Neurocrine Biosciences, INC. | $60.87 | 2025 | |
| Axsome Therapeutics, INC. | $48.55 | 2025 | Auvelity |
| Braeburn INC. | $48.14 | 2024 | Brixadi |
| Merck Sharp & Dohme LLC | $47.72 | 2024 | Vaxelis, Vaxneuvance, Gardasil |
| Indivior INC. | $46.62 | 2024 | Sublocade |
| Uswm, LLC | $41.30 | 2023 | Zimhi, Lucemyra |
| Phadia US INC. | $39.62 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $31.08 | 2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $29.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.25 | 2021 | |
| Sanofi Pasteur INC. | $19.75 | 2023 | |
| Glaxosmithkline, LLC. | $19.65 | 2023 | Pediarix, Bexsero |
| Bioventus LLC | $18.50 | 2025 | Exogen Ultrasound Bone Healing System |
| Teva Pharmaceuticals USA, INC. | $17.69 | 2024 | Austedo Xr |
| Novo Nordisk INC | $17.36 | 2022 | |
| Gilead Sciences, INC. | $16.71 | 2024 | Epclusa |
| Alkermes, INC. | $15.35 | 2025 | Vivitrol |
| Dexcom, INC. | $14.90 | 2022 | |
| Exact Sciences Corporation | $13.30 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.